CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying,…
Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma…
WARREN, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of…
PTX-COVID19-B was well tolerated with no safety signalsNon-inferior neutralizing antibody titer levels versus comparator vaccine, Comirnaty®Providence will initiate a Phase…
SEATTLE, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune…
MARIETTA, Ga., Oct. 19, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental…
The PMDA enters 9th consecutive year of using Certara’s softwarePRINCETON, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Certara, Inc., (Nasdaq:…
Dr. Mark Lowdell, CSO, Presented Latest Data in First Plenary Session at The Innate Killer Summit Europe, London Today BOCA…
Phase 2 investigator-initiated trial to be supported by an NCI grant to Providence Cancer Institute in Portland, Oregon to study…
EDISON, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial…